EU

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca/Oxford’s…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

The state of the hunt:

India inked vaccine supply deals with Bharat Biotech and SII.
  BioNTech upped its 2021 production target for Comirnaty to 2 billion doses—but the Pfizer/BioNTech vaccine faced near-term production slowdowns and delivery lags.
  An African Union-backed supply initiative locked up 270 million vaccine doses for the continent.

 

Vaccines


Approved or authorized vaccines

Sinovac’s inactivated jab notched its first…

The state of the hunt:

The Pfizer/BioNTech vaccine received several new authorizations, including from the European Union.
  Canada joined the U.S. in authorizing Moderna’s jab. .
  Argentina and Belarus became the first countries outside Russia to OK Sputnik V.

 

Vaccines


Approved or authorized vaccines
 
Pfizer and BioNTech will market their BNT162b2 vaccine in the European Union under the brand name Comirnaty after receiving…

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.

 

Vaccines


Approved or authorized vaccines
 
The U.S. FDA granted Emergency Use Authorization (EUA…

The state of the hunt:

Gavi made a preliminary deal with GSK and Sanofi, securing up to 200 million doses of their vaccine candidate for the COVAX Facility.
  British regulators began expedited reviews of vaccines from AstraZeneca and Pfizer, and South Korea also began an initial review of the AstraZeneca candidate.
  A trial of an investigational Lilly mAb failed against advanced Covid-19 cases, and a trial of a Regeneron mAb cocktail in people requiring high-flow…

The state of the hunt:

Phase 3 trials of AstraZeneca’s AZD1222 vaccine candidate resumed in Brazil, Britain, India and South Africa, while U.S. officials voiced safety concerns.
  The United Arab Emirates joined China in issuing emergency approval of a CNBG inactivated vaccine candidate.
  A trial of Lilly’s RA drug Olumiant in combination with remdesivir met its primary endpoint.

 

Vaccines

Phase 3 candidates:
 
Phase 3 trials resumed last…

The state of the hunt:

AstraZeneca commenced a U.S. Phase 3 trial of its AZD1222 vaccine candidate.
  Sanofi/GSK launched the first human trials of their investigational adjuvanted vaccine.
  Germany, Japan and Norway joined the COVAX Facility, which now has commitments from 78 upper- and upper-middle-income countries.

 

Vaccines

Phase 3 candidates:
 
AstraZeneca’s AZD1222 vaccine entered a United States-based Phase 3 trial targeting 30,000…

The state of the hunt:

Moderna inked a $1.5 billion, 100-million-shot supply deal with the U.S. government for its mRNA vaccine candidate.
  The EU sealed a 400-million-dose vaccine deal with AstraZeneca and agreed to a framework with J&J for up to 400 million more.
  Biological E will produce the investigational vaccine from J&J’s Janssen subsidiary.

 

Vaccines

Clinical trials:

Moderna and Pfizer/BioNTech took steps to modify the…